New hope for Tough-to-Treat colon cancer
NCT ID NCT07261709
Summary
This study is testing whether adding a newer drug called fruquintinib works as well as adding the standard drug bevacizumab when combined with another cancer medication for advanced colorectal cancer that has stopped responding to previous treatments. Researchers will enroll 236 patients with metastatic colorectal cancer that has progressed despite at least two prior treatment regimens. The trial aims to determine if the newer combination is at least as effective at controlling cancer growth while being safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY METASTATIC COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the first affiliated hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080
Guangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.